Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
LOS ANGELES, Oct. 19, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Tintri, Inc. (“Tintri” or the “Company”) (Nasdaq:TNTR) concerning possible violations of federal securities laws in connection with its initial public offering on or about June 30, 2017 (the “IPO”). Investors who purchased or otherwise acquired Tintri shares pursuant and/or traceable to the IPO should contact the firm prior to the November 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, Tintri made false and/or misleading statements and/or failing to disclose that the Company experienced distraction, disruption, and sales attrition during its IPO; and as a result, the Company’s statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On September 7, 2017, Tintri held an earnings conference call for the second quarter. During the call, the Company’s Chairman and Chief Executive Officer David Klein stated that “Q2 revenue grew 27% over the same quarter a year ago, at the low end of our expectations,” and that this was “primarily due to distraction, disruption and some sales attrition occurred during and after our IPO.” Upon release of this information, Tintri’s stock price dropped materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/
